Introduction
Castleman disease (CD), also known as angiofollicular or giant lymph node hyperplasia is an uncommon lymphoproliferative disorder, with heterogeneous manifestations ranging from asymptomatic disease to recurrent episodes of widespread lymphadenopathy with systemic symptoms. The exact incidence of CD is unknown, but the estimated number of cases in the US ranges from 30 000 to 100 000 [1] . The disease has become increasingly relevant in recent years given its association with HIV and with human herpesvirus-8 (HHV8).
CD was first described at Massachusetts General Hospial in 1954 by Dr Benjamin Castleman who described a patient with solitary hyperplastic mediastinal lymph nodes characterized by regressively transformed germinal centers [2] . He subsequently reported on 13 patients with benign mediastinal lymphadenopathy, most with follicular hyperplasia and capillary hyalinization [3] . This subgroup is now known as the hyaline vascular variant of CD. During the 1960s, a new variant of CD was described that lacked hyalinization, had concentric sheets of plasma cells surrounding the germinal centers and in the interfollicular space, and was often associated with systemic manifestations [4] . This became known as the plasma cell variant of CD. In addition, given that some patients present with localized lymphadenopathy, whereas others have disseminated disease, CD has also been divided into unicentric CD and multicentric CD (MCD). More recently, a third subtype of CD, known as plasmablastic MCD, has been identified. This subtype is multifocal, behaves more aggressively, and was first described in association with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS). In this variety, involved nodes contain large abnormal plasma cells with prominent nucleoli and copious cytoplasm in the mantle zones [5, 6] (Fig. 1 ). Plasmablastic MCD is found with increased frequency in HIV-infected individuals, and the incidence of HIV-associated MCD appears to be increasing in the highly active antiretroviral therapy (HAART) era [7] .
Because MCD is an uncommon diagnosis, comprehensive clinical studies have not been done, and understanding of the disease is incomplete. This article will discuss what is currently known about the pathophysiology, diagnosis, management, and prognosis of MCD in HIV-infected individuals.
Pathophysiology
HHV8 and cytokine dysregulation including increased levels of vascular endothelial growth factor (VEGF) and a interleukin (IL)-6 have been recognized to have a role in the pathogenesis of MCD.
Human herpesvirus-8
During the emergence of the AIDS epidemic, clinicians recognized that Kaposi's sarcoma and MCD often coexisted [8] [9] [10] . In the 1990s, Kaposi's sarcoma herpesvirus, also known as HHV8, was isolated and linked to a number of diseases including MCD [11] [12] [13] [14] . In the first study linking the cause and pathophysiology of MCD with HHV8, 17 HIV-negative and 14 HIVpositive individuals with MCD, and 34 HIV-uninfected control individuals with reactive lymph nodes and no histopathologic features of MCD, were assessed for presence of HHV8 by PCR in excised lymph nodes. Of the 17 HIV-uninfected participants, 41% showed evidence of HHV8 infection. All 14 of the HIV-infected individuals, but only one of the control patients had HHV8 detectable in lymph nodes [15] . Suda et al. [16] examined 82 paraffinembedded lymph nodes from patients with MCD for the presence of HHV8, which was detected in only three (4%) samples, all from individuals who were HIV-infected. Given this data, it was believed that the HHV8 was always present in HIV MCD; however, the first case report of MCD in an HIV-positive individual with undetectable HHV8 based on PCR and immunohistochemistry (IHC) was reported in 2003 [17] .
Although, this recent report may suggest other possible causes for development of MCD in HIV-infected individuals, other lines of evidence also support the role of HHV8 in the pathogenesis of MCD. First, in HIVinfected individuals, the quantity of HHV8 in peripheral blood mononuclear cells or plasma has been noted to correspond with symptoms during MCD flares [18] [19] [20] [21] [22] [23] [24] .
Additionally, there appears to be a high degree of HHV8 replication, with mostly lytic genes active in infected cells in patients with MCD, and administration of antiviral therapies has been associated with regression of symptoms in some HIV-infected patients with MCD [24] [25] [26] .
Given these data, it is evident that HHV8 plays a role in the pathogenesis of HIV MCD; however, the causality of HHV8 in the development of HIV-associated MCD has not yet been established and should be the subject of future investigations.
Vascular endothelial growth factor
VEGF is a cellular signal protein, which stimulates angiogenesis. Foss et al. [27] examined lymph nodes from eight patients with unspecified variants of CD and compared them with tonsillar tissue in patients with infectious mononucleosis. VEGF was detected by in-situ hybridization (ISH) in five of eight germinal centers in those with CD, and in none of the controls. Nishi et al. [28] examined one patient with the unicentric plasma cell variant of CD and one patient with MCD, both who had elevated levels of serum VEGF which then fell to normal after nodal resection and chemotherapy, respectively. VEGF levels were 100-times higher from the supernatants of the affected nodes compared with a control node, and nearly all plasma cells from the interfollicular region of both nodes stained positive for VEGF by ISH. These studies suggest that VEGF may play a role in the pathogenesis of CD, but further studies are needed to elucidate its role in pathways leading to development of this disease.
Interleukin-6
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A study done in mice showed that expression of a murine IL-6 gene caused an MCD-like syndrome [31] . Additionally, patients have been found to have elevated serum IL-6 levels during symptomatic episodes of MCD, which become normal again after treatment [20, 32, 33] .
One possible source of IL-6 production in MCD may be from cells infected with HHV8. HHV8 encodes a viral homologue of IL-6 (vIL-6), which can stimulate the known human IL-6 (hIL-6) induced signaling pathways [34] [35] [36] [37] [38] . Studies in mice and human cell lines have shown that vIL-6 supports cell growth and survival in vitro in a similar manner to hIL-6. In mice, recombinant vIL-6 induced a marked plasmacytosis similar to that found in MCD, as well as accelerating hematopoesis and inducing VEGF [39] . vIL-6 has also been shown to induce production of hIL-6 in cells harvested from a lymph node of a patient with MCD, thus providing a link between HHV8 infection and higher levels of hIL-6.
Observational studies have also supported the role of HHV8 and vIL-6 in CD. vIL-6 has been found to be expressed in the lymph nodes of both HIV-negative and HIV-positive individuals with CD [40] [41] [42] . Elevated levels of vIL-6 which were noted in the blood of a patient symptomatic with HHV8 associated MCD, decreased with prednisone and foscarnet treatment [43] .
Clinical presentation
Individuals with MCD present with symptoms consistent with an inflammatory process. Affected patients are typically older than those with unicentric disease, with median age at presentation in the 50s-60s [44] . Studies have not found that prevalence varies by gender [45] [46] [47] .
A retrospective study of 20 HIV-infected individuals with MCD showed that the main presenting symptoms were fever, peripheral lymphadenopathy, hepatosplenomegaly, weight loss, respiratory symptoms, and edema [48] . Additionally, all patients had anemia, elevated Creactive protein, polyclonal hypergammaglobulinemia, hypoalbuminemia, and seven patients were pancytopenic.
The increased vascular permeability caused by VEGF can lead to pleural effusions and ascites [49, 50] . The disease can either be persistent with gradual worsening of symptoms or present as episodic exacerbations [51] .
MCD patients often have some manifestations of POEMS syndrome, which is seen in up to 15% of MCD cases [52] . However, peripheral neuropathy and monoclonal paraprotein with or without other features of POEMS are only rarely seen in patients with HIV [53] . IL-6 may cause immune dysregulation, leading to autoimmune phenomena [54] . Autoimmune hemolytic anemia and thrombocytopenia, pure red cell aplasia, acquired factor VIII deficiency, lupus, and myasthenia gravis have all been described.
Diagnosis
The differential diagnosis of HIV-associated MCD should include lymphoma, autoimmune disorders, and viral or bacterial infections. Examination of an excised lymph node is necessary to establish the diagnosis. The histologic characteristics of plasmablastic MCD include the presence of plasmablasts within the mantle zone of B-cell follicles. These plasmablasts are characterized by a moderate amount of cytoplasm and a large vesicular nucleus with 1-2 prominent nucleoli. IHC often reveals nuclear staining of B cells for HHV8associated latent nuclear antigen-1 [55, 56] . The plasmablasts express high levels of cytoplasmic immunoglobulin, that is always IgM lambda restricted [55, 57] . Despite the expression of monotypic IgM lambda, the plasmablasts have polyclonal immunoglobulin gene rearrangements and the HHV8 episomes are also polyclonal [57, 58] .
The diagnosis of active HIV MCD also requires clinical features of active disease. There are no evidence based criteria for establishing a diagnosis of active MCD, but the French Agence Nationale de Recherche sur le SIDA 117 CastlemaB trial group have described criteria to define an attack of HIV MCD [59] . Patients require a fever, a C-reactive protein greater than 20 mg/l in the absence of any other cause, and three of 12 additional clinical findings (see Table 1 ).
In addition to excisional lymph node biopsy, work up in patients with HIV MCD should include HHV8 serology with quantitative HHV8 PCR, CBC, renal and liver function, and assessment for plasma cell dyscrasias including immunoglobulins, serum and urine protein electrophoresis and immunofixation, light chains, bone marrow biopsy and 24 h urine for protein quantification. Patients should also be assessed for organ function with echocardiogram and PFTs. Imaging to assess extent of disease involvement can be done with either CT of the neck, chest, abdomen, and pelvis, or with whole body PET/CT [49] .
Treatment
The gold standard therapy for HIV MCD is yet to be established. Options for therapy include chemotherapy, monoclonal antibodies, immune modulators, and antiviral therapy.
Chemotherapy
The most commonly reported chemotherapy regimens for MCD in the literature are those modeled after the treatment of non-Hodgkin's lymphoma (NHL). Two series reported remissions with chemotherapy lasting anywhere from 1 to 10 years in four out of six patients treated with cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) and in two out of four patients treated with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) [45, 47] . In a large study of 20 patients with HIV-associated MCD, nine patients treated with single agent vinblastine achieved a partial response, but only four patients remained stable with maintenance therapy, and five patients relapsed and required combination chemotherapy with adriamycin, bleomycin, and vincristine (ABV) or partial splenectomy. Four patients received ABV up-front with three having a partial response. Three patients received intermittent cyclophosphamide with partial response [48] . Oral etoposide has also been evaluated in individuals with MCD, with patients achieving a partial response [60] . The combination of chlorambucil and prednisone has been used in studies, with four of nine patients achieving a complete response [45, 47, 51, 61] . More recently, chemotherapy combined with rituximab immunotherapy has shown efficacy [53, 62, 63, 64 ] .
Given the small number of patients reported in these studies, there is little evidence on which to base treatment decisions and insufficient data to prefer one regimen of chemotherapy over another. Often the choice of chemotherapy is made based on how aggressive the disease appears.
Monoclonal antibodies
Tocilizumab is a humanized antihIL-6 receptor monoclonal antibody. In Japan, tocilizumab was administered to 28 HIV-negative patients with MCD who were noted to have improved symptomatology, lymphadenopathy, and inflammatory markers [65] . This agent has been approved for treatment of CD in Japan, but is only approved in the US for treatment of rheumatoid arthritis. Siltuximab is a novel anti-IL-6 monoclonal antibody, which was used for treatment of MCD and unresectable unicentric CD in a phase I study. Interim results reported that 18 of 23 patients achieved clinical benefit, and 12 patients demonstrated objective tumor response. All 11 patients treated with the highest dose of 12 mg/ kg achieved clinical benefit and eight achieved objective response. These data suggest that siltuximab may be effective for treatment of CD [66 ] . Studies are needed to assess the efficacy of tociluzumab and siltuximab for treatment of HIV MCD.
Rituximab is a monoclonal antibody to CD20 that leads to cell death in cells expressing this surface marker. Although HHV8-infected plasmablasts frequently do not express high levels of CD20, several case series and open label studies have evaluated the use of rituximab in HIV-associated MCD. One study evaluated 4 weekly dosage of rituximab at the standard dose of 375 mg/m2 in five patients with HIV MCD. Although two patients died very quickly after initiating therapy, three of the five achieved a complete remission [67] . Another study of 21 patients with newly diagnosed HIV MCD treated with four standard dosage of rituximab reported a radiologic response rate of 67%, overall survival of 95% at 2 years, and disease-free survival of 79% at 2 years [68] . A third study of 24 patients with chemotherapy dependent HIV MCD, reported that 4 weekly standard dosage of rituximab induced a remission of at least 1-year duration in 71% and achieved a 1-year overall survival of 92% [59] . Although these studies suggest efficacy of rituximab for HIV MCD, two case series have described patients with aggressive HIV MCD and organ failure who failed to respond to rituximab monotherapy [69, 70] .
Rituximab has also been studied for retreatment of patients with HIV MCD who had received previous treatment with rituximab. Three patients were rechallenged with rituximab, and all achieved a remission [71] .
A retrospective study analyzed 107 patients with HIV MCD who had received chemotherapy as first-line therapy. Thirty-five of these patients received rituximab at some point after diagnosis of MCD. The study found that 14 of 82 (19%) patients who did not receive rituximab progressed to non-Hodgkin lymphoma (NHL), whereas only one of 35 (3%) in the rituximab group progressed to NHL. The 3-year overall survival was 93% in the treated group versus 74% in the untreated group (P ¼ 0.01) [72 ] . Another retrospective study found that clinical outcomes for patients with HIV MCD were improved during recent years suggesting improved efficacy of rituximab-based treatment strategies [73 ] .
Immune modulators
Corticosteroids have been used to control the inflammation associated with MCD, but have not been studied in clinical trials. In one study, six patients with MCD were treated with glucocorticoids, four of whom did not achieve a lasting response [51] . In another study, three of five patients treated with prednisone achieved a partial response [74] . However, in other case series, the few patients receiving prednisone alone only saw transient improvements while on the drug [45, 46] . A large number of individuals were noted to die of sepsis during therapy, and long-term corticosteroid therapy can be associated with a high risk of infection [46, 51] .
Interferon (IFN) alpha has both immunoregulatory and antiviral properties and was reported to achieve lasting remissions after administration of chronic therapy in two patients with HIV MCD [75, 76] . Thalidomide has immunomodulatory properties and may decrease production of IL-6, and has been described in the treatment of MCD in two HIV-negative individuals [77, 78] .
Antiviral therapy
Several antiherpes drugs including cidofovir, foscarnet, and ganciclovir have been reported to show activity again HHV8 in vitro [79] . However, these agents have had only limited success in treatment of HIV MCD. In studies with cidofovir, zero of seven patients responded [24, 80, 81] . Two of four patients achieved remission with foscarnet [19, 76, 81, 82] . Ganciclovir and valgangiclovir induced remission in one patient and reduced frequency of relapse in two additional patients [83] .
It is uncertain whether HAART usage contributes to control of HIV MCD. Epidemiologic data has shown that the incidence of HIV MCD is increasing in the HAART era [7] . A review of the literature included 48 patients diagnosed with HIV MCD in the HAART era, of whom 44% were on HAART at the time of MCD diagnosis, and of those 20 (83%) had HIV viral loads less than 400 copies/mm 3 [84] . Case reports have also described acute deterioration of MCD symptoms upon starting HAART [19, 85, 86] .
However, other data have suggested that HAART is beneficial to patients being treated for HIV CD. A case series of seven patients with HIV CD on HAART showed a mean duration of survival of 36 months compared with a mean duration of survival of 14 months from a study published before the systematic use of HAART [87] . A case report described an HIV MCD patient who achieved a complete clinical and pathological remission following the use of HAART alone [88] . Another study identified four HIV MCD patients who received HAART alone as treatment with resolution of constitutional symptoms within three months of starting HAART [89] .
Follow-up and prognosis
HIV MCD is often a relapsing and remitting disease. Relapse flares may occur at any CD4 count and are not thought to be prevented by HAART and control of the HIV virus [18, 20, 83, 87, 90] . Thus far, there are few data available on second or subsequent line therapy in these patients. HIV MCD also has a high risk of progression to NHL. In a study of 60 HIV-infected individuals with MCD, and a median follow-up period of 20 months, 14 patients developed HHV8-associated NHL, which is 15-fold the expected incidence in the general HIVpositive population [91] . Similarly in an Australian study of 11 patients with HIV MCD, with a median follow-up of 48 months, four patients developed lymphoma [90] . A few studies have examined imaging methods for monitoring these patients with HIV MCD and have suggested that PET/CT may be useful for detecting active disease [92, 93] .
Conclusion
Given the limited amount of data available, it is difficult to make definitive conclusions regarding the optimal treatment for HIV MCD. Currently the most data are available on the use of rituximab, and this is often used alone or in combination with chemotherapy as first line treatment depending on how aggressive the disease appears in a given individual. All patients with HIV MCD should be followed at regular intervals given the relapsing, remitting nature of the disease. A limited number of studies suggest that PET scans may be useful for monitoring disease activity in these patients, but data are not available in regards to how often scans should be done, or whether they should be done only if a patient exhibits symptoms of recurrence. Randomized, clinical trials are needed to determine the optimal treatment and management of these patients.
